urea has been researched along with Angina Pectoris in 8 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Administration of landiolol using the presently recommended dosage and administration route causes a decrease in HR without aggravation of hemodynamics in patients with normal cardiac function, but in patients with preoperative EF lower than 50%, it may lead to further deterioration of cardiac function due to a decrease in HR." | 6.73 | The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. ( Goto, K; Miyakawa, H; Miyamoto, S; Noguchi, T; Shingu, C, 2007) |
| "Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time." | 2.80 | Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. ( Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA, 2015) |
| "Administration of landiolol using the presently recommended dosage and administration route causes a decrease in HR without aggravation of hemodynamics in patients with normal cardiac function, but in patients with preoperative EF lower than 50%, it may lead to further deterioration of cardiac function due to a decrease in HR." | 2.73 | The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. ( Goto, K; Miyakawa, H; Miyamoto, S; Noguchi, T; Shingu, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greenberg, BH | 1 |
| Chou, W | 1 |
| Saikali, KG | 1 |
| Escandón, R | 1 |
| Lee, JH | 1 |
| Chen, MM | 1 |
| Treshkur, T | 1 |
| Megreladze, I | 1 |
| Wasserman, SM | 1 |
| Eisenberg, P | 1 |
| Malik, FI | 1 |
| Wolff, AA | 1 |
| Shaburishvili, T | 1 |
| Goto, K | 2 |
| Hagiwara, S | 1 |
| Hidaka, S | 1 |
| Yamamoto, S | 1 |
| Kusaka, J | 1 |
| Yasuda, N | 1 |
| Shingu, C | 2 |
| Noguchi, T | 2 |
| GILLAM, PM | 1 |
| PRICHARD, BN | 1 |
| D'iachenko, TC | 1 |
| Verovckiĭ, VE | 1 |
| Ostrovskiĭ, OV | 1 |
| Iakovlev, AT | 1 |
| Lopatin, IuM | 1 |
| Miyamoto, S | 1 |
| Miyakawa, H | 1 |
| Leishman, AW | 1 |
| Sandler, G | 1 |
| Beevers, DG | 1 |
| Fairman, MJ | 1 |
| Hamilton, M | 1 |
| Harpur, JE | 1 |
| Auvinen, S | 1 |
| Konttinen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina[NCT00682565] | Phase 2 | 94 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00682565)
Timeframe: 1 day
| Intervention | seconds (Mean) |
|---|---|
| Mid Dose Active Drug | 41.5 |
| High Dose Active Drug | 40.5 |
| All Placebo | 60.1 |
"This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.~Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina." (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 7 |
| All Placebo | 2 |
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 4 |
| High Dose Active Drug | 2 |
| All Placebo | 1 |
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 0 |
| All Placebo | 1 |
ST Segment Depression measured by Electrocardiography while performing ETT-3. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 1 |
| All Placebo | 2 |
3 trials available for urea and Angina Pectoris
| Article | Year |
|---|---|
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, D | 2015 |
The effect of landiolol on cerebral blood flow in patients undergoing off-pump coronary artery bypass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Cerebrovascular Circulation; Coronary Artery Byp | 2010 |
The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Cardiac Output; Catheterization, | 2007 |
5 other studies available for urea and Angina Pectoris
| Article | Year |
|---|---|
USE OF PROPRANOLOL IN ANGINA PECTORIS.
Topics: Angina Pectoris; Aspartate Aminotransferases; Biomedical Research; Blood; Clinical Enzyme Tests; Dru | 1965 |
[Informative value of plasma biochemical parameters in acute and chronic coronary heart disease].
Topics: Acute Disease; Aged; Angina Pectoris; Bilirubin; Blood Chemical Analysis; Blood Glucose; Blood Prote | 2007 |
Guanethidine and hypertension after five years.
Topics: Albuminuria; Angina Pectoris; Blood Pressure; Cerebrovascular Disorders; Female; Follow-Up Studies; | 1967 |
Antihypertensive treatment and the course of established cerebral vascular disease.
Topics: Angina Pectoris; Antihypertensive Agents; Cardiomegaly; Cerebrovascular Disorders; Diuretics; Female | 1973 |
The diagnostic value of serum LDH isoenzymes and heat-stable and urea-stable LDH measurements.
Topics: Alanine Transaminase; Alkaline Phosphatase; Angina Pectoris; Clinical Enzyme Tests; Electrophoresis; | 1971 |